Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.

Date publication

janvier 2026

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali , Pr KLEINCLAUSS François , Dr BOUSTANI Jihane

Tous les auteurs :
Mezepo G, Khene ZE, Boustani J, Kleinclauss F, Quivrin M, Neftah Y, Mercier J, Bajeot AS, Mardelli C, Pradere B, Seisen T, Hammoud Y, Bouvier E, Jacquey H, Choffel L, Palkowski T, Khalifa J, Benyoucef A, Pasquier D, Brassart C, Marcq G, Khalladi N, Coutte A, Sargos P, Huck C, Rouprêt M, Roumiguie M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41577610

Résumé

Muscle-invasive bladder cancer (MIBC) may present de novo (primary MIBC [pMIBC]) or progress from non-muscle-invasive disease (secondary MIBC [sMIBC]). While sMIBC has been associated with adverse outcomes after radical cystectomy, its prognostic impact in patients undergoing trimodal therapy (TMT) is unclear. We aimed to compare the outcomes between pMIBC and sMIBC in a multicenter cohort treated with bladder-preserving TMT.

Mots clés

Bladder preservation, Chemoradiotherapy, Muscle-invasive bladder cancer, Oncological outcomes, Primary muscle-invasive bladder cancer, Secondary muscle-invasive bladder cancer, Trimodal therapy

Référence

Eur Urol Oncol. 2026 01 22;: